[1] M. Aghighi et al., “Dialysis in iran,” Iran J Kidney Dis, vol. 2, no. 1, pp. 11–5, 2008.
[2] D. of E. United Nations and P. D. Social Affairs, “World population ageing 2013,” N. Y. U. N., 2013.
[3] A. Irish et al., “Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study,” BMC Nephrol., vol. 10, no. 1, p. 1, 2009. DOI: https://doi.org/10.1186/1471-2369-10-1
[4] J. VachharajaniTushar, “Dialysis vascular access selection in elderly patients,” US Nephrol., vol. 6, no. 2, pp. 128–130, 2011. DOI: https://dx.doi.org/10.1111%2Fsdi.12037
[5] C. David, I. Peride, A. Niculae, A. M. Constantin, and I. A. Checherita, “Very low protein diets supplemented with keto-analogues in ESRD predialysis patients and its effect on vascular stiffness and AVF Maturation,” BMC Nephrol., vol. 17, no. 1, p. 131, 2016. DOI: https://doi.org/10.1186/s12882-016-0347-y
[6] C.-C. Yen et al., “Factors affecting fistula failure in patients on chronic hemodialysis: a population–based case–control study,” BMC Nephrol., vol. 19, no. 1, p. 213, 2018. DOI: https://doi.org/10.1186/s12882-018-1010-6
[7] A. J. Jackson, P. Coats, and D. B. Kingsmore, “Pharmacotherapy to improve outcomes in vascular access surgery: a review of current treatment strategies,” Nephrol. Dial. Transplant., vol. 27, no. 5, pp. 2005–2016, 2012. DOI: https://doi.org/10.1093/ndt/gfr552
[8] C. Wong et al., “Liposomal prednisolone inhibits vascular inflammation and enhances venous outward remodeling in a murine arteriovenous fistula model,” Sci. Rep., vol. 6, 2016. DOI: https://doi.org/10.1038/srep30439
[9] T. Lee, “Novel paradigms for dialysis vascular access: downstream vascular biology–is there a final common pathway?,” Clin. J. Am. Soc. Nephrol., p. CJN–03490413, 2013. DOI: https://doi.org/10.2215/CJN.03490413
[10] M. Khavanin Zadeh, F. Gholipour, Z. Naderpour, and M. Porfakharan, “Relationship between vessel diameter and time to maturation of arteriovenous fistula for hemodialysis access,” Int. J. Nephrol., vol. 2012, 2012. DOI: http://dx.doi.org/10.1155/2012/942950
[11] C. Tantithamthavorn, A. E. Hassan, and K. Matsumoto, “The impact of class rebalancing techniques on the performance and interpretation of defect prediction models,” IEEE Trans. Softw. Eng., 2018. DOI: https://doi.org/10.1109/TSE.2018.2876537
[12] J. Jiarpakdee, C. Tantithamthavorn, and A. E. Hassan, “The impact of correlated metrics on defect models,” ArXiv Prepr. ArXiv180110271, 2018.
[13] A. Ghasemi and S. Zahediasl, “Normality tests for statistical analysis: a guide for non-statisticians,” Int. J. Endocrinol. Metab., vol. 10, no. 2, p. 486, 2012. DOI: https://dx.doi.org/10.5812%2Fijem.3505
[14] J. C. Duque et al., “Arteriovenous fistula maturation in patients with permanent access created prior to or after hemodialysis initiation,” J. Vasc. Access, vol. 18, no. 3, pp. 185–191, 2017. DOI: https://doi.org/10.5301/jva.5000662
[15] P. A. Conz, C. Crepaldi, and G. La Greca, “Slow maturation of arterio-venous fistula in seven uremic patients: use of Ash Split Cath® as temporary, prolonged vascular access,” J. Vasc. Access, vol. 1, no. 2, pp. 51–53, 2000. DOI: https://doi.org/10.5301/jva.5000662
[16] R. Usman, M. Jamil, and M. Naveed, “High preoperative neutrophil-lymphocyte ratio (NLR) and red blood cell distribution width (RDW) as independent predictors of native arteriovenous fistula failure,” Ann. Vasc. Dis., p. oa–17, 2017. DOI: https://doi.org/10.3400/avd.oa.17-00016
[17] A. Kirkpantur et al., “Association of serum lipid profile and arteriovenous fistula thrombosis in maintenance hemodialysis patients,” Blood Purif., vol. 26, no. 4, pp. 322–332, 2008. DOI: https://doi.org/10.1159/000132388
[18] Y. Al-Solaiman, A. Jesri, Y. Zhao, J. D. Morrow, and B. M. Egan, “Low-sodium DASH reduces oxidative stress and improves vascular function in salt-sensitive humans,” J. Hum. Hypertens., vol. 23, no. 12, p. 826, 2009. DOI: https://doi.org/10.1038/jhh.2009.32
[19] C. Rugale, S. Delbosc, J.-P. Cristol, A. Mimran, and B. Jover, “Sodium restriction prevents cardiac hypertrophy and oxidative stress in angiotensin II hypertension,” Am. J. Physiol.-Heart Circ. Physiol., vol. 284, no. 5, pp. H1744–H1750, 2003. DOI: https://doi.org/10.1152/ajpheart.00864.2002
[20] A. S. Todd et al., “Dietary salt loading impairs arterial vascular reactivity,” Am. J. Clin. Nutr., vol. 91, no. 3, pp. 557–564, 2010. DOI: https://doi.org/10.3945/ajcn.2009.28645
[21] S. K. Morton, A. J. Rodriguez, D. R. Morris, A. P. Bhandari, J. V. Moxon, and J. Golledge, “A systematic review and meta-analysis of circulating biomarkers associated with failure of arteriovenous fistulae for haemodialysis,” PloS One, vol. 11, no. 7, p. e0159963, 2016. DOI: https://doi.org/10.1371/journal.pone.0159963
[22] T. Ishii et al., “Duplex ultrasound for the prediction of vascular events associated with arteriovenous fistulas in hemodialysis patients,” J. Vasc. Access, vol. 17, no. 6, pp. 499–505, 2016. DOI: https://doi.org/10.5301/jva.5000595
[23] J. T. Salonen, K. Nyyssönen, H. Korpela, J. Tuomilehto, R. Seppänen, and R. Salonen, “High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men.,” Circulation, vol. 86, no. 3, pp. 803–811, 1992. DOI: https://doi.org/10.1161/01.cir.86.3.803
[24] M. A. Kaygin et al., “The relationship between arteriovenous fistula success and inflammation,” Ren. Fail., vol. 35, no. 8, pp. 1085–1088, 2013. DOI: https://doi.org/10.3109/0886022X.2013.815100
[25] F. Sarı, H. Taşkapan, A. Sığırcı, and B. Akpınar, “Evaluation of Risk Factors for Arteriovenous Fistula Failure in Patients Undergoing Hemodialysis.,” Erciyes Med. JournalErciyes Tip Derg., vol. 38, no. 1, 2016. DOI: https://doi.org/10.5152/etd.2016.005